nivolumab,ipilimumab
bms
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'niche-2']
 paramount results from the niche-2 trial presented by #myriam chalabi ! neoadjuvant immunotherapy for crc : major pathological response in 95% of patients!! 
Medical Oncology, Gastrointestinal tumors. Focus on colorectal cancer, Vall d'Hebron Institute of oncology (@VHIO)